Sufficient life expectancy as an eligibility criterion in cancer clinical trials
Cancer Letters · 2024-12 · 607 · 217322
DOI: 10.1016/j.canlet.2024.217322 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2024-12. Verfasst von Nicole D Agaronnik und 1 weiteren Autor:innen. Beteiligte Einrichtung: Harvard Medical School, United States. Electronic address: Nicole_agaronnik@hms.harvard.edu. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 13 Literaturangaben. Gefördert von: Institute for Quantitative Social Science, Harvard University, Harvard University.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Harvard Medical School, United States. Electronic address: Nicole_agaronnik@hms.harvard.edu.
- Health Policy Research Center-Mongan Institute, Massachusetts General Hospital, United States; Department of Medicine, Harvard Medical School, United States.
Förderung
- Institute for Quantitative Social Science, Harvard University
- Harvard University
Zitieren
APA
Agaronnik, N. D., & Iezzoni, L. I. (2024). Sufficient life expectancy as an eligibility criterion in cancer clinical trials. Cancer Letters, 607, 217322. https://doi.org/10.1016/j.canlet.2024.217322
Vancouver
Agaronnik ND, Iezzoni LI. Sufficient life expectancy as an eligibility criterion in cancer clinical trials. Cancer Letters. 2024;607:217322. doi:10.1016/j.canlet.2024.217322
BibTeX
@article{Agaronnik2024,
author = {Agaronnik, Nicole D and Iezzoni, Lisa I},
title = {Sufficient life expectancy as an eligibility criterion in cancer clinical trials},
journal = {Cancer Letters},
year = {2024},
volume = {607},
pages = {217322},
doi = {10.1016/j.canlet.2024.217322}
}
EUVIMED